Patents Examined by Michael Schmitt
  • GPR 17 agonists and screening assay
    Patent number: 8623593
    Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: January 7, 2014
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Evi Kostenis, Andreas Spinrath, Stephanie Hennen, Lucas Peters, Christa E. Muller, Rhalid Akkari, Younis Baqi, Kirsten Ritter
  • Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
    Patent number: 8623889
    Abstract: The invention provides novel compounds having the general formula: wherein X1 is N or N+O?, and one of X2, X3 and X4 is N or N+—O? and the remainder of X2, X3 and X4 is C. R2, R3, R4, R5, R6. A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: January 7, 2014
    Assignee: Genentech, Inc.
    Inventors: Joseph P. Lyssikatos, Lewis J. Gazzard, Emily Hanan, Samuel Kintz, Hans Edward Purkey
  • Hepatitis C virus inhibitors
    Patent number: 8618153
    Abstract: This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: December 31, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Makonen Belema
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 8614204
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: December 24, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 8609646
    Abstract: The present invention relates to methods and compounds for decreasing the expression of hepcidin, a protein associated with regulation of iron metabolism.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 17, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Skin treatment compositions
    Patent number: 8609642
    Abstract: The present invention relates to compositions, kits and methods for treating skin at sites of concerns such as infectious lesions and/or points of insertion of an insertable medical device to prevent contamination such as infections or protein absorption that may interfere with the function of the device. The composition can be a topical skin treatment composition that includes polyethylene glycol (PEG), triclosan, one or more of a salicylate, bronopol, and an acrylic emulsion, and, optionally, a solvent.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: December 17, 2013
    Assignee: Ex-Tek, LLC
    Inventor: Richard James Whitbourne
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 8604013
    Abstract: The present invention relates to methods for treating anemia in a subject having a low percent transferrin saturation by administering to the subject an effective amount of a compound that inhibits hypoxia-inducible factor prolyl hydroxylase activity.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 10, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 8604012
    Abstract: The present invention relates to methods and compounds for increasing serum iron in a subject.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: December 10, 2013
    Assignee: Fibrogen, Inc.
    Inventors: Stephen J. Klaus, Christopher J. Molineaux, Thomas B. Neff, Volkmar Guenzler-Pukall, Ingrid Langsetmo Parobok, Todd W. Seeley, Robert C. Stephenson
  • Fused piperidine compound and pharmaceutical containing same
    Patent number: 8604030
    Abstract: The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula (1): (wherein, ring A represents a C10-14 aryl group or 5- to 10-membered heterocyclic group, X represents N—R7, a sulfur atom or an oxygen atom, R1, R2, R2?, R3 and R3? independently represent a hydrogen atom, C1-6 alkyl group or C3-6 cycloalkyl group, and R4, R5 and R6 independently represent a hydrogen atom or halogen atom), or a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: December 10, 2013
    Assignee: Kowa Company, Ltd.
    Inventors: Masanori Ashikawa, Toshiharu Morimoto, Hajime Yamada, Shunji Takemura, Tatsuaki Nishiyama, Takeshi Doi, Hiroyuki Ishiwata
  • CDKI pathway inhibitors and uses thereof
    Patent number: 8598344
    Abstract: The invention relates to compounds for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: December 3, 2013
    Assignee: Senex Biotechnology
    Inventors: Donald C. Porter, Igor B. Roninson, Mark P. Wentland
  • Compounds for treating proliferative disorders
    Patent number: 8581004
    Abstract: Disclosed are compounds of Formula (I) and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: November 12, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Teresa Kowalczyk-Przewloka, Lijun Sun
  • Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them
    Patent number: 8575376
    Abstract: A compound with general formula I for treatment of various diseases of the central nervous system, in treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, PTSD and other diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addictions, multiple sclerosis, epilepsy and gliomas.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: November 5, 2013
    Assignees: Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky, V.V.I., Fyziologicky Ustav Akadamie Ved Ceske Republiky, V.V.I., Psychiatricke Centrum Praha
    Inventors: Hana Chodounska, Eva Stastna, Vojtech Kapras, Ladislav Kohout, Jirina Borovska, Ladislav Vyklicky, Karel Vales, Ondrej Cais, Lukas Rambousek, Ales Stuchlik, Vera Valesova
  • Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
    Patent number: 8563593
    Abstract: The present invention relates to formulations of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), pharmaceutical packs or kits thereof, and methods of treatment therewith.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: October 22, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Rossitza Gueorguieva Alargova, Irina Nikolaevna Kadiyala, Noreen Tasneem Zaman
  • Parenteral formulation of clopidogrel
    Patent number: 8563574
    Abstract: Described herein are ways to solubilize clopidogrel for parenteral administration containing clopidogrel and a diluent NNDMA (N,N-dimethylacetamide); useful in the prevention of platelet aggregation in acute coronary syndrome, acute myocardial infarction or to prevent platelet facilitated thrombosis following coronary angioplasty and/or coronary stenting.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: October 22, 2013
    Inventors: John C. Somberg, Vasant V. Ranade
  • Pyrazolopiperidine compounds as CCR1 receptor antagonists
    Patent number: 8546442
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: October 1, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rajashekhar Betageri, Brian Nicholas Cook, Darren DiSalvo, Christian Harcken, Daniel Kuzmich, Pingrong Liu, John Lord, Can Mao, Hossein Razavi
  • Treatment of acne using derivatives of 5-aminolevulinic acid
    Patent number: 8546447
    Abstract: The invention provides use of a photosensitiser, which is a derivative (e.g., an ester) of 5-aminolevulinic acid (5-ALA) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention or treatment of acne.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 1, 2013
    Assignee: Photocure ASA
    Inventors: Aslak Godal, Jo Klaveness, Hilde Morris
  • Benzylic oxindole pyrimidines
    Patent number: 8546443
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R5 to R10, A, L1, B, m and p are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: October 1, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Treu, Stephan Karl Zahn, Patricia Amouzegh, Cristina Lecci, Heather Tye
  • Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
    Patent number: 8524691
    Abstract: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: September 3, 2013
    Assignee: The Medicines Company
    Inventors: Evelyne Dietrich, Ranga Reddy, Kelly Tanaka, Ting Kang, Yanick LaFontaine, Adel Rafai Far
  • Compounds for the treatment of hepatitis C
    Patent number: 8507683
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: August 13, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, John F. Kadow, Rajesh Onkardas Bora, Kumaravel Selvakumar
  • Aryl guanidine FF-ATPase inhibitors and related methods
    Patent number: 8497307
    Abstract: The invention provides to a family of aryl guanidine—based F1F0—ATPase inhibitors, e.g., mitochondrial F1F0—ATPase inhibitors, methods for their discovery, and their use as therapeutic agents for treating certain disorders.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: July 30, 2013
    Assignee: The Regents of the University of Michigan
    Inventors: Gary D. Glick, Peter Toogood, Gina Ney